

# Timothy J Break

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9666896/publications.pdf>

Version: 2024-02-01

10  
papers

554  
citations

1040056

9  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

1016  
citing authors

#	ARTICLE	IF	CITATIONS
1	Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. <i>JCI Insight</i> , 2016, 1, .	5.0	219
2	Aberrant type 1 immunity drives susceptibility to mucosal fungal infections. <i>Science</i> , 2021, 371, .	12.6	84
3	Oral epithelial IL-22/STAT3 signaling licenses IL-17-mediated immunity to oral mucosal candidiasis. <i>Science Immunology</i> , 2020, 5, .	11.9	66
4	Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	52
5	Critical Adverse Impact of IL-6 in Acute Pneumovirus Infection. <i>Journal of Immunology</i> , 2019, 202, 871-882.	0.8	33
6	CXCR3 Is Dispensable for Control of Mucosal <i>Candida albicans</i> Infections in Mice and Humans. <i>Infection and Immunity</i> , 2015, 83, 958-965.	2.2	31
7	VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant <i>Candida albicans</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 151-155.	3.0	26
8	VT-1598 inhibits the in vitro growth of mucosal <i>Candida</i> strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2089-2094.	3.0	23
9	Infections in the monogenic autoimmune syndrome APECED. <i>Current Opinion in Immunology</i> , 2021, 72, 286-297.	5.5	15
10	Response to Comments on "Aberrant type 1 immunity drives susceptibility to mucosal fungal infections" <i>Science</i> , 2021, 373, eabi8835.	12.6	5